Company News

Florida Virtual Entrepreneur Center Highlights Captozyme CEO

Helena Cowley, CEO of Captozyme, which was named a GrowFL Company To Watch in 2017, was the company's first employee. She never set out to be an entrepreneur, but says the process of growing the company has certainly turned her into one. 

Read Helena's interview with Florida Virtual Entrepreneur Center and discover her tips for aspiring entrepreneurs.
 

PRESS RELEASE: Captozyme Among Florida Companies to Watch

Captozyme, a Gainesville-based biotechnology company, is among 50 statewide companies expected to see significant growth over the next several years. Captozyme was selected from more than 500 nominees for Florida Companies to WatchSM, a statewide program managed by economic development group GrowFL, in association with the Edward Lowe Foundation.  

PRESS RELEASE: Nephure™ Obtains Self-Affirmed GRAS Notification

PRESS RELEASE: Nephure™ Obtains Self-Affirmed GRAS Notification

Nephure, an oxalate degrading enzyme manufactured by Captozyme, has received self-affirmed GRAS notification. Expected for market release in 3rd QTR.

PRESS RELEASE: CAPTOZYME OPENS UP NEW HEADQUARTERS

GAINESVILLE, FL; April 26, 2017- Upon graduating from the University of Florida’s Innovation Hub, local biotechnology company, Captozyme Inc., recently acquired a newly constructed facility to house their new headquarters at 1622 NW 55th Place. The company plans to consolidate all operations there during the coming months, and is proud to be part of the developing biotechnology scene of Gainesville.

Captozyme graduates from the Innovation Hub

Captozyme is pleased to announce that they have officially graduated from the University of Florida's Innovation Hub. In the fall of 2014 Captozyme found its home at the university's incubator for start-up companies in the technology and biotechnology fields. Now, a little over 2 years later, Captozyme graduates with 14 employees and a new office and lab space in north Gainesville. 

The Innovation Hub has helped over 60 companies launch since opening their doors in 2010, and Captozyme is proud to be among them.  Beyond providing office and lab space, the Innovation Hub helps its companies flourish by providing guidance and educational events to encourage collaboration and teach vital skills to beginning businesses. Captozyme is grateful to the Innovation Hub for all the hard work they do for their companies and the community around them.

 

Captozyme Presents at the 2017 Florida Venture Forum

Captozyme was recently honored in being one of the 20 companies chosen to present at the Florida Venture Forum out of more than 100 applicants. The Florida Venture Forum's mission is to connect emerging Florida-based companies with resources and capital nationwide.  

“The Conference is always a must-attend event for anyone involved in the venture capital and private equity industry in Florida,” added Casey Swercheck, Chairman of the 2017 Florida Venture Capital Conference and Vice President of Capitala Group.

This year the conference was held in Orlando, Florida on February 2-3.

PRESS RELEASE: CAPTOZYME SECURES $3.4 MILLION TO CONTINUE ENZYME RESEARCH

GAINESVILLE, FL; January 20, 2017 – Captozyme Inc., a biotechnology company based in Gainesville, FL, recently raised $3.4 million. Captozyme plans to invest this money into the manufacturing and launch of Nephure, an oxalate-degrading enzyme to facilitate a low-oxalate diet.

“We are humbled by the confidence put in us to continue our research and develop products and aid us in getting these products to the marketplace,” says Aaron Cowley, CEO of Captozyme. “Our team has spent significant time and effort in making our products live up to the expectations of our most important stakeholders, the people who are currently struggling on a low-oxalate diet.”

A low-oxalate diet and normal consumption of calcium is useful in normalizing relatively high urinary oxalate. Sticking to the diet can be hard, especially when there can be a wide range of discrepancies online about what food is generally considered oxalate rich. Nephure’s goal is to make being healthier, easier; it takes away this uncertainty by breaking down the oxalate compound in food.

A low-oxalate diet should limit oxalate intake to 40 to 50 mg each day, though in the USA oxalate intake is estimated to average 150-200 mg each day. Captozyme’s pre-clinical data of Nephure features:

  • 40-60% reduction in urinary oxalate when administered to dogs with high urinary oxalate
  • Successful creation of oxalate-free craft beer and ready to drink tea and juices

About Captozyme

Captozyme is a biotechnology company that is dedicated to helping people better manage their diets and overall health. Through Nephure they have created a product that allows people to enjoy the food they love without the consequences of adding oxalate to their body. Learn more about Captozyme at Captozyme.com and stay up to date on Nephure for when it launches in the summer.

Contact:

Aaron Cowley

Captozyme Inc.

785.760.3128

Aaron.cowley@captozyme.com

 

Captozyme COO Featured in Florida's High Tech Corridor Magazine

Florida's High Tech Corridor Council has been promoting collaboration among Corridor universities since 1996 and continues to make great achievements in economic development initiatives.

Captozyme is excited to have our COO, Helena Cowley, presented as one of the "Faces of Technology" in this year's publication. 

Captozyme Accepted to the NIH Commercialization Accelerator Program (CAP)

The NIH Commercialization Accelerator Program (CAP) is designed to help some of the agency’s most promising small life science and healthcare Phase II grantees develop their commercial businesses and transition their SBIR/STTR-funded technologies into the marketplace. Applicants are selected via a competitive process for a limited number of slots in the program.

See more information here: https://sbir.nih.gov/cap